IBD in 2010: Optimizing treatment and minimizing adverse events

[1]  A. Rastogi,et al.  The impact of pre‐endoscopy proton pump inhibitor use on the classification of non‐erosive reflux disease and erosive oesophagitis , 2010, Alimentary pharmacology & therapeutics.

[2]  S. Shariq,et al.  Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. , 2010, Journal of Crohn's & colitis.

[3]  S. Targan,et al.  Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis , 2010, Gut.

[4]  F. Zerbib,et al.  Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH‐impedance study in healthy subjects , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[5]  G. Boeckxstaens,et al.  Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. , 2010, Gastroenterology.

[6]  K. Harnett,et al.  Increased TRPV1 gene expression in esophageal mucosa of patients with non‐erosive and erosive reflux disease , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[7]  Christopher F. Martin,et al.  764 One Year Newborn Outcomes Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry , 2010 .

[8]  C. Ell,et al.  Long-Term Outcome of Microscopic Esophagitis in Chronic GERD Patients Treated With Esomeprazole or Laparoscopic Antireflux Surgery in the LOTUS Trial , 2010, The American Journal of Gastroenterology.

[9]  E. Savarino,et al.  Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance–pH Off Therapy , 2010, The American Journal of Gastroenterology.

[10]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[11]  S. Targan,et al.  Prospective randomized open‐label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid‐refractory ulcerative colitis† , 2010, Inflammatory bowel diseases.

[12]  C. Porter,et al.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  J. West,et al.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study , 2010, The Lancet.

[14]  M. Vieth,et al.  Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project. , 2010, Human pathology.

[15]  K. DeVault.  Arbaclofen Placarbil Decreases Postprandial Reflux in Patients With Gastroesophageal Reflux Disease , 2010 .

[16]  M. Vieth,et al.  Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus , 2009, Gut.

[17]  H. Sokol,et al.  Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle , 2009, Gut.

[18]  M. Regueiro,et al.  A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. , 2007, Gastroenterology.